@article{Annemiek Broijl_Marie-José Kersten_Wendimagegn Ghidey Alemayehu_Mark-David Levin_Okke de Weerdt_Edo Vellenga_Ellen Meijer_Shulamit Wittebol_Bea C. Tanis_Petra B. Cornelisse_Marian Stevens-Kroef_Gerard M.J. Bos_Pierre W. Wijermans_Henk Lokhorst_Pieter Sonneveld_2016, place={Pavia, Italy}, title={Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma}, volume={101}, url={https://haematologica.org/article/view/7695}, DOI={10.3324/haematol.2015.132431}, number={4}, journal={Haematologica}, author={Annemiek Broijl and Marie-José Kersten and Wendimagegn Ghidey Alemayehu and Mark-David Levin and Okke de Weerdt and Edo Vellenga and Ellen Meijer and Shulamit Wittebol and Bea C. Tanis and Petra B. Cornelisse and Marian Stevens-Kroef and Gerard M.J. Bos and Pierre W. Wijermans and Henk Lokhorst and Pieter Sonneveld}, year={2016}, month={Mar.}, pages={e149-e152} }